EWTX
$30.50
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Intraday
Recent News
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
One analyst tracking the biotech has become notably more bullish on its future.
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results
Why the latest MESA data matters for Edgewise Therapeutics stock Edgewise Therapeutics (EWTX) just released three and a half year data from its MESA open label extension study of sevasemten in Becker muscular dystrophy, highlighting stable motor function in a setting where decline is typically expected. See our latest analysis for Edgewise Therapeutics. Following the MESA update and recent conference appearances, Edgewise Therapeutics’ share price of $29.59 sits against a 90 day share price...
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next
Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of investigational drug sevasemten in Becker muscular dystrophy, showing sustained stabilization of patient function over 3.5 years and a continued favorable safety profile. An unusually high 99% of eligible participants from prior sevasemten trials chose to enroll in MESA, underlining strong patient retention and interest in this potential first-in-class therapy for a disease with no approved...
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference
Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the company’s neuromuscular and cardiovascular pipeline during a discussion hosted by Leerink Partners’ Joseph Schwartz, with CEO Kevin Koch and COO Behrad Derakhshan providing comm
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.